Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis

Particle and Fibre Toxicology

Solomon Mequanente Abay¹ 

[1] Department of Pharmacology, School of Medicine, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia

关键词: Meta-analysis;    Systematic review;    Primaquine;    Artemether-lumefantrine;    Artesunate;    Malaria transmission blocking;   

Others  :  824479
DOI  :  10.1186/1756-3305-6-278

 received in 2013-06-05, accepted in 2013-09-20,  发布年份 2013

【 摘 要 】

Background

Among the currently used drugs in malaria case management, artemisinin derivatives and primaquine have an impact on the transmissible stages of Plasmodium falciparum. Hence, they reduce the transmission of the parasite from the patient to the mosquitoes. The present study aimed to assess evidence for this hypothesis from controlled trials.

Methods

All controlled clinical trials evaluating the transmission blocking activity of artemisinin derivatives and primaquine with or without other antimalarials were included in this systematic review. PubMed, Google Scholar, Web of Science, ScienceDirect, Medscape and the Cochrane library were systematically searched without language, publication status or date restrictions. The literature references were also scanned manually. The last search was run on July 15, 2013. Search terms included artemisinin derivatives, primaquine, malaria transmission, transmission blocking/reducing drugs and mosquito infection. The outcome measure was the mosquito infectivity rate after treatment of patients. Data were compared using odds ratio (OR), in random effects models.

Results

Nine trials with a total of 13,831 mosquitoes were included in the meta-analysis. After combining the trials, the transmission of P. falciparum to Anopheles mosquitoes were lower in artesunate, artemether-lumefantrine and primaquine groups as compared with their control counterparts with OR of 0.36 (95% confidence interval (CI), 0.14-0.90), 0.49 (95% CI, 0.31-0.79) and 0.09 (95% CI, 0.01-0.73); respectively. In non-comparative longitudinal studies, the use of a single-dose of primaquine was shown to deter the transmission of malaria briefly.

Conclusion

Evidence on the transmission blocking effect of artemisinin derivatives and primaquine is conclusive. Trials evaluating the combined impact of artemisinin derivatives and primaquine on malaria transmission is urgently needed.

【 授权许可】

   
2013 Abay; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]World Health Organization: [http://www.who.int/gho/malaria/en] webciteGlobal Health Observatory.
• [2]World Health Organization: [http://www.who.int/malaria/media/world_malaria_report_2012_facts/en/] webciteMalaria- factsheet on the world malaria report 2012.
• [3]Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-31.
• [4]World Health Organization: [http://www.who.int/mediacentre/news/releases/2012/malaria_20120424/en/] webciteMedia center- World malaria day.
• [5]Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996, 347:1654-8.
• [6]World Health Organization: [http:/ / www.who.int/ malaria/ publications/ atoz/ Policy_brief_IPTp-SP_implementation _11april2013.pdf.pdf] webciteWHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP).
• [7]Okumu FO, Moore SJ: Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future. Malar J 2011, 10:208.
• [8]Centers for Disease Control and Prevention: [http://www.cdc.gov/malaria/tools_for_tomorrow/research_areas.html] webciteMalaria: Current and Future Research.
• [9]Wilairatana P, Krudsood S, Tangpukdee N: Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas. Korean J Parasitol 2010, 48:179-182.
• [10]Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ: Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 2008, 7:125.
• [11]Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009, 6:e1000097.
• [12]Higgins JPT, Green S: [http://www.cochrane-handbook.org] webciteCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.
• [13]Wallace BC, Schmid CH, Lau J, Trikalinos TA: Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009, 9:80.
• [14]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [15]Drakeley CJ, Jawara M, Targett GAT, Walraven G, Obisike U, Coleman R, Pinder M, Sutherland CJ: Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health 2004, 9:53-61.
• [16]Targett G, Drakeley C, Jawara M, Seiden L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P: Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 2001, 183:1254-9.
• [17]Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 2006, 193:1151-9.
• [18]Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GAT: Reduction of malaria transmission to Anopheles mosquitoes with a six-dose of regimen o Co-artemether. PLoS Med 2005, 2:e92.
• [19]Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD: Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain ofPlasmodiumfalciparum. Bull World Health Organ 1968, 38:625-32.
• [20]Clyde DK, Miller RM, Music SI, McCarthy VC: Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam. Am J Trop Med Hyg 1971, 20:1-5.
• [21]Schrol JB, Moustgaard R, Gøtzsche PC: Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol 2011, 11:22.
• [22]Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T: Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013, 207:1637-45.
• [23]Clyde DK, DuPont HI, Miller RM, McCarthy VC: Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Malaya. Trans R Soc Trop Med Hyg 1970, 64:834-838.
• [24]Burgess RW, Bray RS: The Effect of a Single Dose of Primaquine on the Gametocytes, Garnetogony and Sporogony of Laverania falciparum. Bull World Health Organ 1961, 24:451-6.
• [25]Young MD: The effect of small doses of primaquine upon malaria infections. Indian J Malariol 1959, 13:69-72.
• [26]Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ: The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 1994, 107:709-11.
• [27]Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez MG, Ghani AC: Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010, 7:e1000324.
• [28]Lengeler C: Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004., 2CD000363
• [29]Fletcher KA, Evans DAP, Gilies HM, Greaves J, Bunnag D, Harinasuta T: Studies on the pharmacokinetics of primaquine. Bull World Health Organ 1981, 59:407-12.
• [30]Carmona-Fonseca J, Arango E, Blair S: Gametocytemia in falciparum malaria treated with amodiaquine or artesunate. Biomedica 2008, 28:195-212.
• [31]Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, Oguche S, Ezeiru VI, Aina OO: Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria. Malar J 2008, 7:172.
• [32]Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D’Alessandro U, Djimdé A, Karema C, Guthmann JP, Hamour S, Ndiaye JL, Mårtensson A, Rwagacondo C, Sagara I, Same-Ekobo A, Sirima SB, van den Broek I, Yeka A, Taylor WR, Dorsey G, Randrianarivelojosia M: Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009, 8:203.
• [33]Sowunmi A, Nkogho OO, Okuboyejo TM, Gbotosho GO, Happi CT, Adewoye EO: Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children. Malar J 2009, 8:297.
• [34]Osorio L, Gonzalez I, Olliaro P, Taylor WR: Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia. Malar J 2007, 6:25.
• [35]Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ: Activities of artesunate primaquine against asexual and sexual stages parasites in falciparum malaria. Antimicrob Agents Chemother 2004, 48:1329-34.
• [36]Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ: Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, 10:673-81.
• [37]Eliana M, Yulieth A, Carmona-Fonseca J: Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Trop 2012, 122:177-82.
• [38]Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, Hawley WA, Lobo NF, Ter Kuile FO: The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013, 56:685-93.
• [39]Shah NK, Schapira A, Juliano JJ, Srivastava B, Macdonald PD, Poole C, Anvikar A, Meshnick SR, Valecha N, Mishra N: A non-randomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing the post-treatment circulation of Plasmodium falciparum gametocytes. Antimicrob Agents Chemother 2013, 57:2948-54.
• [40]Mwangangi JM, Muturi EJ, Muriu SM, Nzovu J, Midega JT, Mbogo C: The role of Anopheles arabiensis and Anopheles coustani in indoor and outdoor malaria transmission in Taveta District, Kenya. Parasit Vectors 2013, 6:114.
• [41]Lwetoijera DW, Kiware SS, Mageni ZD, Dongus S, Harris C, Devine GJ, Majambere S: A need for better housing to further reduce indoor malaria transmission in areas with high bed net coverage. Parasit Vectors 2013, 6:57.
• [42]Tchouassi DP, Quakyi IA, Addison EA, Bosompem KM, Wilson MD, Appawu MA, Brown CA, Boakye DA: Characterization of malaria transmission by vector populations for improved interventions during the dry season in the Kpone-on-Sea area of coastal Ghana. Parasit Vectors 2012, 5:212.